Guggenheim raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $78 from $75 and keeps a Buy rating on the shares. The firm was “a bit puzzled by the negative stock reaction following what we see as strong results and a solid guide,” notes the analyst, who recommends investors to be buyers on the weakness.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TARS:
- Tarsus Pharmaceuticals: Strong Earnings and Growth Potential Make It a Buy
- Tarsus Pharmaceuticals: Undervalued Growth Potential and Acquisition Appeal Reinforce Buy Rating
- Tarsus Pharmaceuticals price target lowered to $60 from $62 at Barclays
- Tarsus Pharmaceuticals Reports Strong 2024 Financial Results
- Tarsus Pharmaceuticals price target lowered to $70 from $75 at BofA